NovoCure (NVCR) Enterprise Value (2016 - 2025)
NovoCure (NVCR) has disclosed Enterprise Value for 12 consecutive years, with -$447.7 million as the latest value for Q4 2025.
- Quarterly Enterprise Value rose 53.36% to -$447.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$447.7 million through Dec 2025, up 53.36% year-over-year, with the annual reading at -$447.7 million for FY2025, 53.36% up from the prior year.
- Enterprise Value hit -$447.7 million in Q4 2025 for NovoCure, down from -$344.6 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$129.4 million in Q1 2025 to a low of -$970.3 million in Q3 2022.
- Historically, Enterprise Value has averaged -$623.2 million across 5 years, with a median of -$884.6 million in 2021.
- Biggest YoY gain for Enterprise Value was 85.13% in 2025; the steepest drop was 441.15% in 2025.
- Year by year, Enterprise Value stood at -$937.7 million in 2021, then fell by 3.38% to -$969.4 million in 2022, then soared by 74.98% to -$242.6 million in 2023, then plummeted by 295.72% to -$959.9 million in 2024, then surged by 53.36% to -$447.7 million in 2025.
- Business Quant data shows Enterprise Value for NVCR at -$447.7 million in Q4 2025, -$344.6 million in Q3 2025, and -$911.5 million in Q2 2025.